Background: An increase in the number of anti-citrullinated protein antibodies (ACPA) reactivities precede RA onset, and may be involved in the pathogenesis of the disease. The presence of ACPA is associated with radiographic progression in RA, and it has been suggested that ACPAs with different reactivities may be associated with different phenotypes of RA. Objectives: To assess the prevalence of baseline ACPA reactivities in an inception cohort of early RA patients, including subgroups based on anti-CCP/RF status, and to compare the findings to healthy controls. Methods: 217 DMARD-naïve early RA patients from the ARCTIC trial (1) were analysed. Radiographs were scored according to van der Heijde Sharp (vdHS) score. Anti-CCP status was analysed by FEIA (pos. if ≥10 IU/mL) and RF by ELISA (pos. if ≥25 IU/mL). ACPA titres (AU/ml) were considered pos. if above the 98-perc. of values in 619 non-RA subjects. Analysis of 13 ACPA reactivities targeting citrullinated peptides from fibrinogen, alpha-1 enolase, vimentin, fillagrin and histone was performed at baseline in patients and 94 controls (blood donors matched for age/gender/smoking), using a multiplex chip-based assay (2). (85) 7 (18) 130 (84) 29 (46) 159 ( (80) 3 (8) 119 (77) 26 (41) 145 (67) 1 (1) CEP1 4 137 (77) 3 (8) 117 (76) 23 (37) 140 (65) 1 (1) Fil307-324 cit 4 134 (75) 2 (5) 113 (73) 23 (37) 136 ( (68) 2 (5) 99 (64) 24 (38) 123 ( (65) 1 (3) 96 (62) 21 (33) 117 (54) 2 (2) H3 1-30 cit 4 106 (60) 1 (3) 93 (60) 14 (22) 107 ( (58) 2 (5) 90 (58) 15 (24) 105 (48) (14) 3 (8) 21 (14) 6 (10) 27 (12) 2 (2) 1 Mean (SD), 2 n (%), 3 Median [IQR], 4 ACPA reactivity, n positive (%).
Results: Baseline characteristics are presented in the Background: Interleukin 33 (IL-33) is a cytokine related to amplification of the articular inflammation in rheumatoid arthritis (RA) animal models. Elevated IL-33 serum levels have been described in RA patients, suggesting a possible participation of this cytokine in the physiopathology of the disease.
1,2 IL-33 soluble receptor (sST2) is a decoy receptor that functions as an inhibitor of the interaction of the transmembrane receptor with IL-33. Objectives: To identify the association between serum levels of IL-33 and its soluble receptor (sST2) with clinical and laboratory characteristics of RA. Methods: Cross-sectional observational study in which RA patients were submitted to clinical and laboratorial evaluation. IL-33 and sST2 serum levels were measured by ELISA (R&D System Inc, Minneapolis, MN, USA). Results: 102 RA patients were included, 92,5% women, mean age of 55,5±10 years and mean disease duration of 17,6±9,5 years. Eighty-four (82,4%) patients had seropositive RA. The median (interquartile range) IL-33 serum level was 69.1 pg/ml (31.6 -114.5). Higher scores on the visual analogue scale (VAS) of disease activity assessed by the examiner were associated with higher IL-33 values (CI95%: 0.01-0.05). In the group of patients with high titres of rheumatoid factor (RF), IL-33 levels were higher, compared to the group with negative RF (95% CI: 0.55 -2.34). In 34 (33.3%) patients, IL-33 was undetectable and the presence of metabolic syndrome 4 represented a 63% lower chance (OR =0.37, 95% CI: 0.15-0.90) of having IL-33 detected. In addition, 1-unit increase in HAQ-DI increased by 2.43 times the chance of detecting IL-33 (95% CI: 1.23 -4.80). The median sST2 serum level was 469.8 pg/ml (336.3-651). sST2 was associated with worse functional capacity by the classification of Steinbroker 5 (IC95%: 0.09 -0.5), use (current or in the past) of tobacco (95% CI: 0.02 -0.53) and use of leflunomide (95% CI: 0.05 -0.53). There was no correlation between IL-33 and sST2 levels. Conclusions: These findings may suggest that both IL-33 and its soluble receptor play a role as a marker of RA severity and functional disability. The negative association of IL-33 with metabolic syndrome is in agreement with the possible protective role of this cytokine in relation to lipid metabolism.
